Background: Protection against helminths consists of adaptive responses by T H 2 cells and innate responses by group 2 innate lymphoid cells (ILC2s), with these latter being well characterized in mice but less so in human subjects. Objective: We sought to characterize human circulating ILC2s and compare their functional profile with that of autologous T H 2 cells. Methods: Circulating ILC2s and T H 2 cells were isolated by means of fluorescence-activated cell sorting and magnetic cell sorting and expanded in vitro. ILC2s were then stimulated with phorbol 12-myristate 13-acetate plus ionomycin, IL-25 plus IL-33 (IL-25/IL-33), or a mixture of Toll-like receptor ligands to evaluate their ability to produce cytokines, express CD154, and induce IgE production by autologous B cells. Cytokines and transcription factor gene methylation were assessed. Results: ILC2s expressed GATA-3, retinoic acid orphan receptor (RORC) 2, and RORa; were able to produce IL-5, IL-13, and IL-4; and, accordingly, were characterized by demethylation of IL4, IL13, IL5, GATA3, and RORC2, whereas the IFNG, IFNG promoter, and TBX21 regions of interest were methylated. ILC2s expressed TLR1, TLR4, and TLR6, and TLR stimulation induced IL-5 and IL-13 production. Moreover, ILC2s expressed CD154 in response to phorbol 12-myristate 13-acetate plus ionomycin, IL-25/IL-33, or a mixture of TLR ligands. Stimulated ILC2s also induced IgM, IgG, IgA, and IgE production by B cells. Finally, circulating ILC2s from atopic patients were not different in numbers and frequency but expressed higher IL-4 levels than those from nonatopic subjects. Conclusion: This study provides the first evidence that human ILC2s can express CD154 and stimulate the production of IgE
T H 2 cells have long been considered key players during adaptive immune responses to infectious extracellular parasites, such as helminths, 1 as well as being responsible for the development of asthmatic and allergic inflammatory disorders. 2, 3 Indeed, by secreting IL-4 and IL-13, T H 2 cells instruct B cells to produce IgG 1 and IgE, and by secreting IL-5, they can activate eosinophils. 4 Moreover, through IL-13 production, T H 2 cells also directly act on epithelial and smooth muscle cells. 5 In addition to T H 2 cells, group 2 innate lymphoid cells (ILC2s) are also capable of producing IL-4, IL-13, or both, and in the steady state they are considered the major producers of IL-5. 6, 7 The master transcription factor of ILC2s is the same as for T H 2 cells (ie, GATA-3), but also retinoic acid orphan receptor (ROR) a is important for their differentiation. 8 ILC2s differ from T H 2 cells mainly because of the lack of T-cell receptor (TCR), and they are activated by cytokines, such as IL-25, IL-33, and thymic stromal lymphopoietin (TSLP). 9, 10 Because of their similarities in the function and requirement of transcriptional machinery, it has been thought that both T H 2 cells and ILC2s collaborate during type 2 immune responses, including protection against parasites and the genesis of allergic inflammation. This has been clearly demonstrated in murine models. Murine ILC2s preferentially localize to the interface between the host and the environment (lung, intestine, and skin) and respond to epithelium-derived cytokines associated with barrier disruption, such as IL-25, IL-33, and TSLP. 9, 11 ILC2s are a major source of IL-5 and IL-13 in vivo but can also produce IL-4 and IL-9 under more defined conditions. 12 In the lungs ILC2s produce IL-13 only after cytokine stimulation, helminth infection, or both. 13 Although ILC2s are considered low IL-4 producers, expression of IL-4 by ILC2s was reported, especially in response to TSLP and leukotriene D 4 , rather than IL-33. 14 Thus far, human ILC2s are less characterized than murine ILC2s. They were first identified in the fetal and adult gut and lung but also in peripheral blood (PB) and nasal polyps of patients with chronic rhinosinusitis (CRS) and are found to express the chemoattractant receptor expressed on T H 2 cells (CRTH2) and CD161. 15 GATA-3 appeared to be critical for the function of human ILC2s and, together with TSLP and IL-33, induced IL-13 production. 16 However, no reports of extensive exploration of the functional activities of purified human ILC2s are available in the literature.
In this study we purified and characterized human circulating ILC2s from healthy subjects and compared in vitro-expanded progenies with the in vitro-expanded progenies of autologous In the circulation of atopic patients, ILC2s were found to be present in frequencies and numbers comparable with those found in nonatopic healthy subjects, but their ability to produce IL-4 in response to PMA/I appeared to be significantly higher. Thus this study provides the first evidence that human ILC2s can express CD154 and produce IL-13 and IL-5 in response to IL-25/IL-33 or Mix TLR-ligand and are therefore able to induce IgE antibody production by autologous B lymphocytes. Moreover, they have the potential to produce higher amounts of IL-4 in atopic than in nonatopic subjects.
METHODS Subjects
PB samples were obtained from 15 healthy volunteers and 11 allergic patients recruited for quantification and functional evaluation of circulating ILC2s. Patients' ages ranged between 17 and 56 years (mean, 27.6 years), and there were 6 female and 5 male patients. Patients have received diagnoses of allergic rhinitis and some of them also of bronchial asthma with 1 or more sensitizations to inhalant allergens. Total and specific serum IgE levels were evaluated by using the ImmunoCAP assay with the Phadia 250 instrument (Thermo Scientific, Waltham, Mass).
The procedures followed in the study were in accordance with the ethical standards of the Regional Committee on Human Experimentation.
Reagents
The medium used was RPMI 1640 (Seromed, Berlin, Germany) supplemented with 2 mmol/L L-glutamine, 1% nonessential amino acids, 1% pyruvate, 2 3 10 25 mol/L 2-mercaptoethanol (all from Gibco Laboratories, Grand Island, NY), and 10% FCS (EuroClone, Milan, Italy). Fluorochromeconjugated anti-CD3, anti-CD4, anti-CD15, anti-CD45, anti-CD123,  anti-CD154, anti-CD161, anti-Lin-1 (anti-CD3, anti-CD14, anti-CD16,  anti-CD19, anti-CD20, and anti-CD56), anti-CD20, anti-CD138, anti-IFN-g,  anti-IL-2, anti-IL-4, anti-IL-5, anti-IL-13, anti-TNF-a, and anti-GM-CSF  mAbs and 
Cytokine and transcription factor intracellular staining
PBMCs from patients and healthy subjects, as well as in vitro-expanded ILC2 and T H 2 cell lines, were stimulated with PMA/I (10 ng/mL and 1 mmol/L, respectively) for 6 hours (the last 4 hours in the presence of 5 mg/mL brefeldin A), fixed in formaldehyde 2%, and evaluated for intracellular cytokine production with a BD LSRII flow cytometer (BD Biosciences). The in vitro-expanded cell lines were stimulated as described above for 6 hours and processed with the Human Foxp3 Staining Set Kit (eBioscience, San Diego, Calif), according to the manufacturer's instructions, to evaluate transcription factor expression in association with cytokines. Briefly, stimulated cells were fixed with Fixation/ Permeabilization buffer diluted 1:4 and then permeabilized in the presence of Permeabilization buffer 1X and stained with the fluorochrome-conjugated mAbs anti-GATA-3 and anti-RORgt or isotype control (eBioscience). Stained cells were analyzed by means of LSR II flow cytometry.
Confocal microscopy
ILC2 and T H 2 cell lines were resuspended in complete medium (3 3 10 5 cells/mL) and seeded on polylysine-coated glass slides. Cells were then incubated for 40 minutes at 378C and 5% CO 2 in RPMI 1640. Then cells were washed in PBS, pH 7.2, and incubated for 20 minutes at room temperature with rabbit IgG (1 mg/mL). Cells were then incubated with an anti-CD45 mAb (1:5, BD Biosciences) for 30 minutes at room temperature. Cells were then fixed in formaldehyde (4% in PBS, pH 7.2) and then incubated for 30 minutes at room temperature in buffer containing TOPRO-3 dye (0.2 mmol/L; Life Technologies, Grand Island, NY) for nuclear counterstaining. Cells were then washed in PBS, pH 7.2, for 5 minutes, and the slides were mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, Calif). Microscopic images were taken with the LSM 510 META Zeiss confocal microscope system (Carl Zeiss, Jena, Germany) by using a 403 oil immersion lens corresponding to 3400 magnification. For image analysis, Confocor 2 (Carl Zeiss) software was used.
Evaluation of cytokines in supernatants
Cells (1.5 3 10 5 ) derived from in vitro-expanded ILC2 and T H 2 cell lines were stimulated in 150 mL (final concentration, 1 3 10 6 cells/mL) in the absence or presence of PMA/I or IL-25/IL-33 (50 ng/mL each) or Mix TLR-ligands (LPS, 100 ng/mL; Pam3Cys, 1 mg/mL; and chitin, 1 mg/mL; only ILC2 lines) or anti-CD2/CD3/CD28 beads (Miltenyi Biotech; only T H 2 cell lines). After 3 days of culture, IL-13, IL-4, IL-5, IL-2, IFN-g, TNF-a, and GM-CSF cytokine levels in ILC2 and Th2 cell line-derived supernatants were evaluated by using the CBA Flex Set Assay, according to the manufacturer's instruction (BD Biosciences).
Absolute blood cell counts
Trucount Tubes (BD Biosciences) were used for determining absolute numbers of ILC2s and T H 2 cells in PB of patients and healthy subjects. Fresh whole blood (100 mL) was added into the Trucount Tube and then stained with 100 mL of fluorochrome-conjugated mAb mix. After 15 minutes, red blood cells were lysed with NH 4 Cl and then evaluated with a BD LSRII flow cytometer (BD Biosciences). The absolute cell count was obtained, multiplying the number of positive cell events by the number of Trucount Tube beads and dividing by the number of Trucount bead events. 
CD154 expression

Immunoglobulin production
Autologous B cells (2 3 10 5 ) isolated as CD19
1 cells by using immunomagnetic cell sorting, as previously described, 17 were cocultured with 1 3 10 5 cells from ILC2 lines stimulated in the presence of IL-25/IL-33 or Mix TLR-ligands or with 1 3 10 5 cells from T H 2 cell lines stimulated with anti-CD3 mAb (100 ng/mL). Some experiments were performed in the same coculture conditions for ILC2s or T H 2 cells with B cells in the absence or presence of blocking anti-CD154 mAb (5 mg/mL; BioLegend, San Diego, Calif) or a combination of blocking anti-IL-4 and anti-IL-13 mAbs (5 mg/mL each; R&D Systems). On day 10, supernatants from each cell culture were collected and evaluated by using a homemade ELISA for IgM, IgG, IgA, and IgE content. 4 cells from T H 2 cell lines stimulated with anti-CD3 mAb in 96-well round-bottom plates. After 24, 48, and 72 hours, cells were recovered, stained for surface antigen to identify the cell subsets in the coculture (CD20, CD4, and CD161) in association with fluorescein isothiocyanate-conjugated Annexin V (BD Biosciences) and propidium iodide (5 mg/mL; Invitrogen, Carlsbad, Calif), and evaluated by using LSRII flow cytometry. Viable B cells were defined by the frequency of Annexin V-negative propidium iodide-negative cells among CD20 1 cells. 
Annexin V staining
Carboxyfluorescein succinimidyl ester proliferation assay
DNA methylation analysis
DNA methylation was evaluated by using bisulfite cloning and a sequencing approach. Genomic DNA was extracted with the DNA Blood Mini Kit (Qiagen, Hilden, Germany), as previously described, 18 followed by bisulfite conversion with the EpiTect Bisulfite Kit (Qiagen), according to the manufacturer's instructions. Bisulfite-treated DNA was PCR amplified with bisulfite-specific primers (listed in Table E1 in this article's Online Repository at www.jacionline.org) and then cloned into pCR2.1 vector (Invitrogen). Cloned products were then transformed into chemically competent Escherichia coli TOP10 cells (Invitrogen). Plasmid DNA from at least 15 colonies for each population was recovered and then sequenced by means of Sanger sequencing (GATC Biotech AG, Constance, Germany). Finally, sequences were analyzed with BISMA software. 19 RNA isolation, cDNA synthesis, and real-time quantitative RT-PCR Total RNA was extracted by using the RNeasy Micro Kit (Qiagen) and treated with DNase I to eliminate possible genomic DNA contamination. TaqMan RT-PCR was performed, as previously described. 18 Primers and probes used were purchased from Life Technologies. Quantification of cell numbers was performed, and results were normalized on glyceraldehyde-3-phosphate dehydrogenase expression.
Tissue samples
Nasal polyp tissue, obtained on the same day of surgery from 2 atopic patients, was digested with 1 mg/mL Collagenase A (Sigma-Aldrich) and shaking at 378C for 90 minutes and then filtered to obtain a single-cell suspension. Cells were stained for flow cytometric analysis to identify ILC2 and T H 2 cells.
Statistics
The Mann-Whitney or paired Student t test was used for statistical analysis by using Origin Software (OriginLab Corporation, Northampton, Mass). P values of .05 or less were considered significant.
RESULTS
Isolation and ex vivo characterization of human ILC2s
CRTH2
1 cells were first isolated from PB of healthy subjects by means of immunomagnetic cell sorting. CRTH2
1 cells were then stained with fluorochrome-conjugated mAbs specific for the lineage markers CD161 and CD45. ILC2s and T H 2 cells were isolated by means of fluorescence-activated cell sorting gating on CD45 
1 cells, respectively. Purified ILC2s recovered by using this procedure were usually less than 0.1% CD45 1 cells. The purification procedures and confocal microscopy morphology of both purified cell populations are shown in Fig 1, A and B , respectively. Moreover, we investigated the expression of killer cell lectin like receptor G1 (KLRG1), another surface marker associated to the ILC2 subset, 20 and found that it was expressed by virtually all PB ILC2s (data not shown).
The ability of purified ILC2s and T H 2 cells to produce IL-2, IL-4, IL-5, IL-13, TNF-a, GM-CSF, and IFN-g in response to stimulation with PMA/I was then investigated. Ex vivo-isolated ILC2s and T H 2 cells produced GM-CSF, IL-2, IL-4, and IL-13, but not IFN-g. Interestingly, the frequency of T H 2 cells producing IL-4, IL-5, IL-2, TNF-a, and GM-CSF was significantly higher than that of ILC2s, with IL-5 and TNF-a produced mainly by T H 2 cells but not by ex vivo-isolated ILC2s (Fig 1, C and D) . Because of the small number of ex vivo available ILC2s, subsequent experiments were performed on in vitro-expanded ILC2 and T H 2 cell lines. To do this, purified circulating ILC2s were cultured in the presence of allogenic irradiated feeder cells plus IL-2, IL-7, or IL-15. ILC2s proliferated in response to all 3 cytokines, with the best responses obtained in the presence of IL-2 or IL-15, but they did not proliferate in response to other cytokines or growth factors, such as IL-4, IL-12, TSLP, prostaglandin D 2 , IL-25, IL-33, or IL-25/IL-33 (data not shown). Therefore in all subsequent experiments, in vitro expansion of purified ILC2 and T H 2 cells was performed by culturing them in the presence of both feeder cells and IL-2.
As shown in Fig 2, A, under these experimental conditions, the great majority of ILC2s maintained CRTH2 and CD161 expression, whereas only a minority of T H 2 cells, all CRTH2 1 , expressed CD161. When examined by using flow cytometry for their ability to produce cytokines in response to stimulation with PMA/I, most T H 2 cells and ILC2s were found to produce IL-13, IL-4, IL-5, TNF-a, IL-2, and GM-CSF, whereas only a minority of these cells produced IFN-g, IL-17, and IL-22 (Fig 2, B and C) . In any case all ILC2s producing IFN-g, IL-17, or IL-22 also produced IL-13 (Fig 2, C) . The ability of both ex vivo-expanded ILC2s and T H 2 cells to produce cytokines in their supernatants in response to different stimulations was then investigated. Both ILC2s and T H 2 cells produced IL-13, IL-5, IL-4, TNF-a, IL-2, and GM-CSF in response to PMA/I, whereas only ILC2s and not T H 2 cells produced IL-13, IL-5, and GM-CSF in response to IL-25/IL-33. Moreover, T H 2 cells produced IL-13, IL-5, IL-4, and GM-CSF in response to anti-CD3/anti-CD28 stimulation. IFN-g was found at low levels in supernatants of either ILC2s or T H 2 cells stimulated only with PMA/I (Fig 2, D) . Of note, we also found appreciable levels of IL-4, TNF-a, and IL-2 in ILC2 supernatants after PMA/I but not IL-25/IL-33 stimulation.
Expression of the transcription factors GATA3, RORA, RORC2, and TBX21 in in vitro-expanded ILC2s and T H 2 and T H 1 cells was then analyzed by using real-time RT-PCR (in this case we examined also T H 1 cells to have a cell phenotype different from type 2 cells for comparison). Of note, both ILC2s and T H 2 cells expressed RORA mRNA, whereas the RORC2 transcription factor was expressed by ILC2s but not by T H 2 cells (Fig 2, E) . Moreover, although GATA3 mRNA was highly expressed by both ILC2s and T H 2 cells, TBX21 mRNA was present at very low levels in both cell populations (Fig 2, E) . As expected, T H 1 cells expressed very low levels of RORA, RORC2, and GATA3 but significantly higher levels of TBX21 when compared with both ILC2s and Th2 cells (Fig 2, E) . Flow cytometric analysis of transcription factors showed that ILC2s and T H 2 cells express similar protein of 8 experiments) . E, Real-time quantitative PCR analysis of GATA3, RORA, RORC, and TBX21 mRNA levels on ILC2, T H 2, and T H 1 cell lines (means 6 SEs of 6 experiments). *P < _ .05, **P < _ .01, and ***P < _ .001, ILC2s vs T H 2 cells or indicated by bar. levels of GATA-3, whereas protein expression levels of RORgt on ILC2s was higher than that on T H 2 cells but lower than that on T H 17 cells (the latter was used to have a positive population as control of RORgt staining; see Fig E1, A, in this article's Online Repository at www.jacionline.org). Moreover, flow cytometric analysis of transcription factors in association with IL-13 showed that virtually all in vitro-expanded ILC2s were positive for GATA-3 and that all RORgt 1 ILC2s expressed IL-13 also (see Fig E1, B) .
ILC2s exhibit low methylation levels of IL4, IL5, IL13, GATA3, and RORC2 gene loci Epigenetic control of gene expression has been shown to play a pivotal role in the organization of both the innate and adaptive immune responses, allowing development and maintenance of lineage-specific cell subsets. For this reason, we hypothesized that these mechanisms could be involved also in the development of ILC populations. We investigated the DNA methylation status at cytokine (IL4, IL5, IL13, and IFNG) and transcription factor . #Indicates the number of CpG sites. *P < _ .05 and **P < _ .01.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 3 (GATA3, RORC2, and TBX21) gene loci in ILC2s and T H 2 cells and, as a control, T H 1 cells. In agreement with data obtained at the protein level, the analysis of CpG sites located in the IL4, IL5, and IL13 gene promoters demonstrated low methylation levels in ILC2s and T H 2 cells and high methylation levels in T H 1 cells (Fig 3, A) . Conversely and in agreement with our previous findings, 17 2 regulatory regions located in the IFNG gene locus (conserved noncoding sequence 1 and promoter, respectively) were completely demethylated in T H 1 cells while being intensively methylated in ILC2s and T H 2 cells (Fig 3, A) . With regard to transcription factors, analysis of ROIs in GATA3, TBX21, and RORC2 gene loci revealed GATA3 demethylation and TBX21 methylation in both ILC2s and T H 2 cells, whereas RORC2 appeared to be demethylated in ILC2s and methylated in T H 2 cells (Fig 3, B) . As expected on the basis of our previous findings 17 and mRNA expression analysis, T H 1 cells were characterized by methylation of both RORC2 and GATA3 and demethylation of TBX21 ROIs (Fig 3, B) .
ILC2s can be induced to express CD154 and promote IgE production by B cells
Because of the ability of ILC2s to produce both of the IgE-switching cytokines IL-4 and IL-13, we asked whether the same cells could also be stimulated to induce IgE synthesis by B lymphocytes. As a first step, we asked whether ILC2s could express CD154 because its interaction with CD40 expressed by B cells is critical for the IgE-switching activity of the 2 cytokines. To this end, both ILC2 and T H 2 cell lines were stimulated with PMA/I or IL-25/IL-33. Interestingly, stimulation with PMA/I induced CD154 expression in the majority of ILC2s and T H 2 cells, whereas IL-25/IL-33 stimulated CD154 expression only in a proportion of ILC2s but not in T H 2 cells (Fig 4, A and B) . To prove that human ILC2s were able to induce IgE production, we isolated B cells (CD19 1 cells) from the same donors of ILC2 and Th2 cell lines. ILC2s and T H 2 cells were cocultured with autologous B cells in the absence or presence of IL-25/IL-33 or anti-CD3 mAb, respectively. After 10 days, amounts of IgE, IgA, IgM, and IgG present in the respective supernatants were measured. As shown in Fig 4, D, in the presence of the appropriate stimulant (anti-CD3 for T H 2 cells and IL-25/IL-33 for ILC2s), both T H 2 cell-and ILC2-stimulated B cells produced IgE, IgA, IgM, and IgG. Unstimulated ILC2s or T H 2 cells were not able to induce any immunoglobulin production by B cells (data not shown). In the presence of anti-CD154 blocking mAbs, immunoglobulin production by B cells cocultured with IL-25/ IL-33-stimulated ILC2s or anti-CD3-stimulated T H 2 cells was significantly inhibited (Fig 4, D) . On the other hand, anti-IL-4 and anti-IL-13 blocking mAbs only slightly reduced IgE production induced by ILC2s and were ineffective with regard to that induced by T H 2 cells (Fig 4, E) .
Moreover, we investigated ILC2 expression of additional molecules that can contribute to the induction of immunoglobulin production. 21 In particular, we evaluated this expression by using real-time RT-PCR of mRNA for B cell-activating factor of the TNF family (BAFF), a proliferation-inducing ligand (APRIL), and delta like canonical Notch ligand 1 (DLL1), and we found that in vitro-expanded ILC2s had significantly higher mRNA levels of DLL1 compared with T H 2 cell lines, whereas mRNA levels of BAFF and APRIL were low in both populations (see Fig E2, A, in this article's Online Repository at www.jacionline.org). Finally, expression of BAFF, APRIL, and DLL1 was not modified by IL-25/IL-33 stimulation for 6 or 12 hours (see Fig E2, B) . We then investigated the effects of ILC2s on B cells also in terms of survival, proliferation, and plasmablast differentiation. In particular, we found that there was no difference in the frequency of viable B cells between unstimulated or IL-25/IL-33-stimulated ILC2s, as well as between unstimulated or anti-CD3-stimulated T H 2 cells (see Fig E3, A, in this article's Online Repository at www.jacionline.org). Moreover, IL-25/IL-33-stimulated ILC2s induced a significant proliferation of B cells, as did anti-CD3-stimulated T H 2 cells (see Fig E3, B) . Regarding plasmablast differentiation, the acquisition of CD138 on B cells was appreciable at very low levels (< _5%) in B cells cocultured for 10 days with stimulated ILC2s or T H 2 cells (data not shown).
ILC2s express TLRs, and their triggering can induce CD154 expression and promote IgE production Because ILC2s, unlike T H 2 cells, do not possess the TCR and therefore cannot be activated through antigen recognition, we asked whether they express TLRs and can be activated through a possible triggering of the latter. When analyzed for TLR mRNA expression by using real-time RT-PCR, ILC2s exhibited higher mRNA levels of TLR1, TLR4, and TLR6 than T H 2 cells (Fig 5, A) . Therefore the ability of the same cells to produce IL-4, IL-5, and IL-13 and to express CD154 in response to a Mix TLR-ligand (Pam3Cys, LPS, and chitin) was investigated. The Mix TLR-ligands induced CD154 expression (Fig 5, B) and IL-5 and IL-13 production but not IL-4 production (Fig 5,  C) only by ILC2s, whereas T H 2 cells were not activated by this type of stimulation. Interestingly, when ILC2s were stimulated with the same Mix TLR-ligand, they were able to induce production of IgE, IgM, IgA, and IgG cells by cocultured autologous B cells (Fig 5, D) . In the presence of an anti-CD154 blocking mAb, we observed a significant reduction of all immunoglobulin class production (Fig 5, D) , whereas use of anti-IL-4 and anti-IL-13 blocking mAbs induced a significant reduction only of IgE production (Fig 5, E) . 
Circulating ILC2s in atopic subjects
Frequencies and numbers of circulating ILC2s and T H 2 cells were then measured in a group of atopic subjects and compared with values for the same cells found in the circulation of nonatopic subjects. No differences between the 2 groups of subjects were found (Fig 6, A) . It is also of note that there was no relationship between the frequencies and numbers of circulating ILC2s and T H 2 cells in atopic subjects and their IgE serum levels (Fig 6, B) . Interestingly, when the ability of ILC2s and T H 2 cells to produce cytokines was evaluated, it was found that ILC2s produced higher IL-4 levels in atopic than nonatopic healthy subjects (Fig 6, C) . Moreover, evaluating the frequency of ILC2s and T H 2 cells in nasal polyps tissue from allergic patients, we found enrichment of especially ILC2s compared with that seen in PB (Fig 6, D) .
DISCUSSION
ILC2s are a recently discovered subpopulation of cells involved in the innate immune response against nematodes, and like T H 2 cells of the adaptive immunity, they also play some role in allergic inflammation. 9, 10 These cells have been well characterized in mice, but there is no systematic characterization of ILC2s in human subjects. This is also because there are differences between different investigative groups about cell-surface markers that define human ILC2s. Mjosberg et al 16 defined ILC2s as Lin 2 CRTH2 1 cells and found them to be present in the fetal and adult gut, as well as in PB, and they appeared to be enriched in nasal polyps of patients with CRS. These cells were responsive to IL-25 and IL-33 and produced large amounts of IL-13. 16 Other groups have defined human ILC2s as expressing CD25 (IL-2 receptor a), ST2 (IL-33 receptor), the prostaglandin D 2 receptor, or a combination of these markers. 22 Barnig et al 23 examined the presence of ILC2s in PB by defining these cells as Lin 2 CD127
1
DP2
1
, and they did not find any difference between healthy subjects and patients with mild or severe asthma. Moreover, the same group reported the presence of ILC2s in human lungs by defining these cells as CD117 1 CD161 1 tryptase-negative cells to distinguish them from mast cells. 23 Walford et al 24 demonstrated that the number of ILC2s was increased in the nasal mucosal tissue from patients with CRS with nasal polyps compared with those with CRS without nasal polyps. Miljikovic et a, 25 by defining ILC2s as Lin 
DP2
1 , were also observed in the skin of patients with psoriasis. 28 These cells produced IL-13 but neither IL-4 nor IL-9.
Thus it appears from the literature that the identification and functional activities of human ILC2s are dependent of the markers used for their definition and/or might even be a heterogeneous mixture of cells showing a different behavior. However, no reports fully exploring the functional activities of purified and expanded human ILC2s are available thus far.
In this study we purified and characterized circulating human ILC2s from healthy subjects by defining these cells as 
CRTH2
1 and compared in vitro-expanded progenies with the in vitro-expanded progenies of autologous purified T H 2 cells, which were defined as CD3
Both ex vivo-purified and in vitro-expanded ILC2s and T H 2 cells produced IL-4, IL-5, and IL-13 but also TNF-a and IL-2 in response to stimulation with PMA/I and exhibited IL13, IL4, IL5, GATA3, RORA, and RORC2 gene demethylation, whereas their IFNG conserved noncoding sequence 1, IFNG promoter, and TBX21 genes were heavily methylated. To our knowledge, this represents the first epigenetic characterization of cytokines and transcription factors of human ILC2s.
Both ILC2s and T H 2 cells proliferated in response to IL-2, IL-15, and IL-7. ILC2s and T H 2 cells also produced IL-13, IL-5, IL-4, IL-2, TNF-a, and GM-CSF in their supernatants in response to stimulation with PMA/I; however, ILC2s, but not T H 2 cells, produced IL-13, IL-5, and GM-CSF in response to IL-25/IL-33, whereas T H 2 cells produce IL-13, IL-4, IL-5, and GM-CSF in response to anti-CD3/anti-CD28 stimulation. The amount of cytokines produced was higher in anti-CD3/anti-CD28-stimulated T H 2 cells than in IL-25/IL-33 stimulated ILC2s, even if it is not easy to perform an exact comparison because of the different magnitude of these stimulations, the first being a polyclonal stimulation that mimics all antigens together and the second a response to some cytokines. Either ILC2s or T H 2 cells under any of these stimulatory conditions produced undetectable levels of IFN-g and produced low levels of IFN-g only in response to PMA/I. In any case flow cytometric intracellular staining of cytokines and transcription factors showed that all IFN-g-producing ILC2s also produced IL-13 and that all ILC2s expressed GATA-3 at the protein level.
These findings allow us to exclude a contamination of pure ILC1s (IFN-g 1
IL-13 2
). Even if a fraction of in vitro-expanded ILC2s produced IL-22 15 and some of them also produced IL-17, we exclude a possible contamination of pure ILC3s because all IL-22-and IL-17-producing cells also coexpressed IL-13. Moreover, the great majority of ILC2s were RORgt 1 , and all RORgt 1 cells expressed IL-13. Both T H 2 cells and ILC2s could be induced to express CD154 by means of stimulation with PMA/I, whereas IL-25/IL-33 induced CD154 expression only in ILC2s. Because ILC2s do not possess, as T H 2 cells do, the TCR and therefore cannot be activated by a specific antigen epitope, we examined whether these cells possess TLRs and can be activated by TLR ligands. Indeed, ILC2s exhibited expression of TLR1, TLR4, and TLR6, and more importantly, they could be activated to produce both IL-13 and IL-5 and to express CD154 through Mix TLR-ligand. Moreover, when cocultured with autologous B cells, ILC2s were able to promote the production of all immunoglobulin isotypes, including IgE, in response to either IL-25/IL-33 or Mix TLR-ligand. This effect is due to the induction of CD154 expression; indeed, blocking of CD154 resulted in a significant reduction of immunoglobulin production. On the other hand, experiments performed in the presence of neutralizing anti-IL-4 and anti-IL-13 mAbs showed a significant reduction of IgE production when B cells were cocultured with TLR ligandstimulated ILC2s, whereas only a slight reduction was observed when coculture was performed with IL25/IL-33-stimulated ILC2s. This difference could be related to the different levels of cytokines produced by ILC2s in response to the 2 different stimulations. Accordingly, we found that IL-13 production in response to IL-25/IL-33 is higher than in the presence of Mix TLR-ligand, and the neutralizing mAbs (added at the beginning of the culture) were not sufficient to block the production of all cytokine amounts. The most interesting observation provided by this study suggests that antigens or even allergens possessing certain TLR-interacting sequences might directly activate ILC2s without the need to induce IL-25/IL-33/TSLP release by damaged epithelial cells. More importantly, our data demonstrate that ILC2s might be able to induce IgE production in response to TLR triggering because of both the induction of CD154 expression and IL-13 production, which are sufficient to promote the production of IgE, even in the absence of IL-4. This suggests that ILC2s might act for protection against nematodes and perhaps even in some types of allergic reactions not only by recruiting eosinophils but also by providing other proinflammatory mechanisms of type 2 immunity, including the production of IgE antibody.
A very important point would be to understand whether ILC2s can also directly respond to allergens. The observation that human ILC2s express TLR and that Mix TLR-ligand can induce CD154 expression and production of both IL-13 and IL-5 by these cells suggests that this event cannot be excluded, even if our preliminary data of stimulation of ILC2s with allergen protein extracts did not show any effect on ILC2 stimulation in terms of CD154 expression and T H 2 cytokine production (data not shown).
Another interesting observation of this study was that in the circulation of atopic patients, ILC2s were present in numbers comparable with those found in nonatopic healthy subjects and that not only ILC2s but also circulating T H 2 cell numbers did not correlate with serum IgE levels. Although in terms of quantity, circulating ILC2s from atopic patients were similar to those from nonatopic patients, their ability to produce IL-4 appeared FIG 6 . Circulating ILC2s in atopic subjects. A, Frequency and numbers of circulating ILC2s and T H 2 cells in nonatopic and atopic subjects (means 6 SEs of 11 subjects of each group). B, Correlation between serum IgE levels and the frequency or the number of circulating ILC2s and T H 2 cells in 11 atopic subjects. C, Flow cytometric intracellular cytokine production by circulating ILC2s and T H 2 cells in nonatopic and atopic subjects in response to PMA/I (means 6 SEs of 10 nonatopic and 9 atopic subjects). D, Representative flow cytometric plots of ILC2s and T H 2 cells in PB and nasal tissue of 2 allergic patients. #Indicates the patient number. *P < _ .05.
to be significantly higher. The pathophysiologic meaning of this latter finding is still unclear. The most likely explanation is that the increased ability to produce IL-4 by ILC2s from atopic subjects simply reflects IL4 gene cluster hyperexpression, which has been demonstrated in atopic subjects at the genetic level, at least in memory T H 2 cells. 29 In conclusion, the results of this study provide the first evidence that human ILC2s produce higher amounts of IL-4 in atopic than nonatopic subjects; more importantly, these cells can be induced to express CD154 and produce IL-13 and IL-5 in response to IL-25/IL-33 or TLR ligands, and therefore they are potentially able to promote the production of IgE antibodies by autologous B lymphocytes, even in vivo. In particular, taking account that our study was performed on circulating PBMCs and that ILC2s were found to be more represented in inflamed tissues, [30] [31] [32] it would be of great interest to define the in vivo relevance of our findings. In fact, the difference between atopic and healthy subjects could be observed, evaluating tissue-specific ILC2s, because we found an increase in the frequency of especially ILC2s in nasal polyp tissue of allergic subjects compared with their PB. Moreover, further investigation of ILC2s in the tissue could be helpful to better define the interaction between ILC2s and B cells in terms of both survival/proliferation and molecules involved in this mechanism, such as BAFF, APRIL, or DLL1, as previously described for splenic ILC3s. 21 In particular, in this study we found that in vitro-expanded ILC2s constitutively express mRNA for DLL1 and that this expression was not affected by IL-25/IL-33 stimulation; moreover, IL-25/IL-33-stimulated ILC2s were able to induce proliferation of autologous B cells.
Type 2 immunity has long been associated with protection against intestinal nematodes, which is mainly dependent on the IL-13 pathway provided by both T H 2 cells and ILC2s. More recently, however, the protective role of type 2 immunity has been extended to noxious xenobiotics, venoms from a variety of ectoparasites (including ticks and mosquitos), hematophagous fluids, and environmental irritants. 33 According to the initial view on the protective function of type 2 immunity, allergy arises when this type of response is inadvertently activated by noninfectious environmental antigens. Thus the allergic response was considered a misdirected and unintended type 2 immune response. The most recent view that type 2 immunity can provide protection against different types of noninfectious noxious environmental factors allows us to support the concept that allergens are not really innocuous environmental antigens, as previously thought. The findings reported in this study, that ILC2s are able to produce not only IL-5 and IL-13 but also high amounts of IL-4, can express CD154, and can even induce the production of IgE by B cells after IL-25/IL-33 stimulation or triggering of their TLRs (Fig 7) , support the view that both adaptive and innate type 2 immunity constitute a complex protective system in which several mechanisms of response are involved.
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Key messages
d The first epigenetic characterization of cytokines and transcription factors in human ILC2s is provided.
d Human circulating ILC2s express TLRs, and TLR stimulation can induce these cells to produce type 2 cytokines, express CD154, and promote IgE production by autologous B cells.
d ILC2s are more abundant in nasal polyps than in PB in atopic patients, and among circulating ILC2s, those from atopic patients have higher frequencies of IL-4-producing cells than those from nonatopic donors. 
